CLOVES syndrome

Last updated
CLOVES syndrome
Other namesCongenital Lipomatous Overgrowth-Vascular malformation-Epidermal nevi-Spinal anomaly syndrome
Congenital Lipomatous Overgrowth-Vascular malformation-Epidermal nevi-Skeletal anomaly syndrome
PI3kinase.png
Mutations affecting PI3kinase are involved in the cause of this condition

CLOVES syndrome is a rare overgrowth syndrome with complex vascular anomalies. CLOVES syndrome affects people with various symptoms, ranging from mild fatty soft-tissue tumors to vascular malformations encompassing the spine or internal organs.

Contents

It is a genetic disorder that results from somatic, mosaic gain-of-function mutations of the PIK3CA gene, and belongs to the spectrum of PIK3CA-related overgrowth syndromes (PROS). This rare condition has no specific treatment and a poor survival rate.

In 2018 French doctor Guillaume Canaud [1] published an article in Nature that demonstrate the efficacy of BYL719 (From cancer), an inhibitor of PIK3CA, in preventing and improving organ dysfunction.

CLOVES syndrome is closely linked to other overgrowth disorders like proteus syndrome, Klippel–Trénaunay syndrome, Sturge–Weber syndrome, and hemihypertrophy, to name a few.

'CLOVES' is an acronym for: [2] [3]

The syndrome was first recognised by Saap and colleagues who recognised the spectrum of symptoms from a set of seven patients. [4] In this initial description the syndrome is named CLOVE syndrome. It is believed that the first description of a case of CLOVES syndrome was written by Hermann Friedberg, a German physician, in 1867. [5] [6]

Causes

Somatic mutations in the PIK3CA have been identified as a cause of CLOVES syndrome. [7] PIK3CA is a protein involved in the PI3K-AKT signalling pathway. Mutations in other parts of this pathway cause other overgrowth syndromes including Proteus syndrome and hemimegalencephaly. [7]

References

  1. "Un traitement contre le syndrome de Cloves, maladie qui déforme les organes et proche de celle d'Elephant man". Sciences et Avenir (in French). 2018-06-14. Retrieved 2022-06-08.
  2. "CLOVES Syndrome". clovessyndrome.org.
  3. Boston Children's Hospital 2013. "CLOVES Syndrome - Boston Children's Hospital". childrenshospital.org.{{cite web}}: CS1 maint: numeric names: authors list (link)
  4. Sapp JC, Turner JT, van de Kamp JM, van Dijk FS, Lowry RB, Biesecker LG (2007). "Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients". Am. J. Med. Genet. A. 143A (24): 2944–58. doi:10.1002/ajmg.a.32023. PMID   17963221. S2CID   29578454.
  5. "CLOVES Syndrome". National Organization for Rare Diseases. Archived from the original on April 2, 2015. Retrieved 24 March 2015.
  6. Alomari, AI; Thiex, R; Mulliken, JB (October 2010). "Hermann Friedberg's case report: an early description of CLOVES syndrome". Clinical Genetics. 78 (4): 342–347. doi:10.1111/j.1399-0004.2010.01479.x. PMID   21050185. S2CID   21069670.
  7. 1 2 Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, Mulliken JB, Bowen ME, Yamamoto GL, Kozakewich HP, Warman ML (2012). "Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome". Am. J. Hum. Genet. 90 (6): 1108–15. doi:10.1016/j.ajhg.2012.05.006. PMC   3370283 . PMID   22658544.